Sorry seventh, yes i had meant that if they are presenting at aaic then we will not hear data until then. Very likely they will do what they did at ctad and present combined data. Longitudinal safety data is probably the most important for this extension. Of course we will hear more on the efficacy front but as of now, everyone wants to see a proper double blinded placebo controlled study with a sufficient sample group to see a confirmatory signal to complement some of the strong signals that have been seen on the p2 study. Hopefully that we have designed a trial to fail as fast as possible, the next trial will be designed to succeed as quickly as possible.
News 
Market Data 
Discover 
AI
